SCYNEXIS (SCYX)
NASDAQ:SCYX
Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$4.52 - $10.48
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$50.64M
Enterprise Value$891.29K
Total Cash (Recent Filing)$59.26M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding9,930,329
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$28.00Price Target Upside4142.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.99
Revenue Forecast (FY)$1.17M
Bulls Say, Bears Say
Bulls Say
Pipeline Diversification (SCY-770)Acquiring SCY-770 diversifies SCYNEXIS beyond antifungals into ADPKD, a rare disease with high unmet need and an FDA-endorsed surrogate endpoint. This provides durable strategic optionality, potential milestone upside and a clear, industry-supported regulatory path to accelerate approval and value realization.
Extended Cash Runway Via PIPEThe $40M PIPE materially lengthens runway to mid-2029, allowing planned Phase 2 start for SCY-770 without immediate financing. This reduces near-term capital risk, supports ongoing R&D and commercialization efforts, and gives management time to hit clinical de-risking milestones that are critical for durable value creation.
Conservative Leverage / Balance Sheet FlexibilityRelatively low debt and conservative leverage provide financial flexibility to fund development programs and absorb operational volatility. This structural strength helps limit insolvency risk, supports negotiated partnerships, and preserves optionality for milestone-driven financing or strategic deals over the medium term.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow means the business is not yet self-sustaining and will likely need additional capital to advance trials or commercial efforts. Over 2-6 months this raises dilution and financing execution risk and constrains discretionary investment in commercialization or pipeline expansion.
Volatile Earnings And Large LossesA sharp reversal into sizable losses and highly negative margins signal weak earnings durability and reliance on lumpy or nonrecurring revenue. Structurally this undermines internal funding capacity, increases dependence on external financing, and heightens execution risk for multi-year clinical programs and commercial expansion.
Capital-Structure Actions And Potential DilutionImplementing a reverse split and concurrent equity actions can indicate share-price and capital-structure stress, and often precedes additional financings. Structurally this raises the prospect of dilution from prior PIPE/warrant arrangements or future raises, affecting long-term shareholder economics and signaling constrained funding alternatives.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $4.52 and its highest was $10.48 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $50.64M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on May 11, 2026. The company reported -$3.36 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$2.373.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.51.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,930,329 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$3.36 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went down -5.34%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.00 (4142.42% Upside)
$28.00 (4142.42% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.6%
Last 30 Days ▲ 15.5%
Last 30 Days ▲ 15.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-57.16%
Trailing 12-Months
Asset Growth
14.30%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Stock 12 Month Forecast
Average Price Target
$28.00
▲(4142.42% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
3.48% Insiders
6.40% Mutual Funds
31.16% Other Institutional Investors
56.75% Public Companies and
Individual Investors